An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants

An Open-Label, Single-Sequence Study to Investigate the Effects of Cyclosporine on the Pharmacokinetics of BMS-986165 at Steady State in Healthy Male Participants

This is an investigational study of Cyclosporine on the experimental medication BMS-986165 in healthy male participants.

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy participant, as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
• Body mass index 18.0 to 32.0 kg/m2
• Weight ≥ 50 kg

Exclusion Criteria:

• Any medical condition that presents a potential risk to the subject and/or may compromise the objectives of the study, including a history of or active liver disease
• History or presence of acute or chronic bacterial, fungal, or viral infection (eg, pneumonia, septicemia) within the 3 months prior to screening
• Known or suspected autoimmune disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status
• History of administration of live vaccines within 60 days before screening
• Any history or risk for tuberculosis (TB)

Other protocol defined inclusion/exclusion criteria could apply